Concordance between proguanil phenotype and CYP2C19 genotype in Chinese

European Journal of Clinical Pharmacology

Volumn 59, Issue 8-9, 2003, Pages 611-614

  Hoskins, Janelle M ^a,b   Shenfield, Gillian M ^a   Gross, Annette S ^a,c  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b University of Sydney   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

CYP2C19; Gene dose effect; Proguanil

Indexed keywords

4 CHLOROPHENYLBIGUANIDE; CYCLOGUANIL; CYTOCHROME P450 2C19; DRUG METABOLITE; PROGUANIL; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG METABOLISM; DRUG URINE LEVEL; ETHNOLOGY; FEMALE; GENE DOSAGE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL;

ADULT; ALLELES; ANTIMETABOLITES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BIGUANIDES; CHLOROGUANIDE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHENOTYPE; TRIAZINES;

EID: 0345598118     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0665-4     Document Type: Article

References (21)

1. Daniel HI, Edeki TI (1996) Genetic polymorphism of S-mephenytoin 4′-hydroxylation. Psychopharmacol Bull 32:219-230
2. Wilkinson GR, Guengerich FP, Branch RA (1989) Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 43:53-76
3. Desta Z, Zhao X, Shin JG, Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913-958
4. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422
5. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598
6. Ward SA, Watkins WM, Mberu E, Saunders JE, Koech DK, Gilles HM, Howells RE, Breckenridge AM (1989) Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol 27:781-787
7. Wanwimolruk S, Pratt EL, Denton JR, Chalcroft SC, Barron PA, Broughton JR (1995) Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori population. Pharmacogenetics 5:193-198
8. Wanwimolruk S, Thou MR, Woods DJ (1995) Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population. Br J Clin Pharmacol 40:166-169
9. Bolaji OO, Sadare IO, Babalola CP, Ogunbona FA (2002) Polymorphic oxidative metabolism of proguanil in a Nigerian population. Eur J Clin Pharmacol 58:543-545
10. Brosen K, Skjelbo E, Flachs H (1993) Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 36:105-108
11. Basci NE, Bozkurt A, Kortunay S, Isimer A, Sayal A, Kayaalp SO (1996) Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population. Br J Clin Pharmacol 42:771-773
12. Bathum L, Skjelbo E, Mutabingwa TK, Madsen H, Horder M, Brosen K (1999) Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol 48:395-401
13. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM (1991) The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 31:689-692
14. Skjelbo E, Mutabingwa TK, Bygbjerg I, Nielsen KK, Gram LF, Broosen K (1996) Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 59:304-311
15. Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T (1995) Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4′-hydroxylation recruited from an Indonesian population. Br J Clin Pharmacol 39: 297-303
16. Hoskins JM, Shenfield GM, Gross AS (1998) Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population. Br J Clin Pharmacol 46:499-504
17. Hoskins JM, Shenfield GM, Gross AS (1997) Modified high-performance liquid chromatographic method to measure both dextromethorphan and proguanil for oxidative phenotyping. J Chromatogr B Biomed Sci Appl 696:81-87
18. Finney DJ (1964) Probit analysis. Cambridge University Press, London
19. Endrenyi L, Patel M (1991) A new, sensitive graphical method for detecting deviations from the normal distribution of drug responses: the NTV plot. Br J Clin Pharmacol 32: 159-166
20. Xie HG (2000) Genetic variations of S-mephenytoin 4′-hydroxylase (CYP2C19) in the Chinese population. Life Sci 66:175-181
21. Nei M, Saitou N (1986) Genetic relationship of human populations and ethnic differences in reaction to drugs and food. Prog Clin Biol Res 214:21-37